Search results for "NAFLD"
Spotlight on liver health in diabetes
A review compared liver outcomes for most classes of diabetes drugs, while a retrospective study looked at glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors head to head. Another study offered a new score for metabolic dysfunction-associated steatotic liver disease.
https://gastroenterology.acponline.org/archives/2024/10/25/8.htm
25 Oct 2024
Spotlight on lean NAFLD
Recent studies looked at the increasing prevalence of nonalcoholic fatty liver disease (NAFLD) in patients without overweight or obesity and compared clinical characteristics of these patients with both healthy controls and patients with obesity and NAFLD.
https://gastroenterology.acponline.org/archives/2020/07/24/5.htm
24 Jul 2020
Heart failure risk increased in patients with NAFLD, meta-analysis finds
Nonalcoholic fatty liver disease (NAFLD) was associated with a 50% increased risk of new-onset heart failure, independent of age, sex, diabetes, hypertension, and other common cardiovascular risk factors, according to an international meta-analysis.
https://gastroenterology.acponline.org/archives/2022/08/26/2.htm
26 Aug 2022
Review examines drugs, lifestyle treatments for NAFLD
The umbrella review included 27 meta-analyses of randomized controlled trials examining the effectiveness of pharmacological interventions and lifestyle modifications, including diet and exercise, for patients with nonalcoholic fatty liver disease (NAFLD).
https://gastroenterology.acponline.org/archives/2022/05/27/2.htm
27 May 2022
Spotlight on NAFLD outcomes
Recent studies found associations between nonalcoholic fatty liver disease (NAFLD) and coronary artery disease, sarcopenia, and mortality.
https://gastroenterology.acponline.org/archives/2022/05/27/5.htm
27 May 2022
Watch out for NAFLD, treat ASAP
Identifying nonalcoholic fatty liver disease (NAFLD) in the primary care setting and deploying effective interventions early can help prevent the slowly progressive disease from becoming an even bigger problem.
https://gastroenterology.acponline.org/archives/2021/04/23/6.htm
23 Apr 2021
Biopsy-proven NAFLD associated with higher rates of MACE
Patients in a Swedish study whose nonalcoholic fatty liver disease (NAFLD) was confirmed on biopsy were more likely to experience incident major adverse cardiovascular events (MACE).
https://gastroenterology.acponline.org/archives/2021/09/24/2.htm
24 Sep 2021
Clinical practice update offers recommendations on noninvasive testing for NAFLD
Noninvasive tests have the potential to significantly enhance the care of patients with nonalcoholic fatty liver disease (NAFLD) by improving detection of advanced fibrosis, according to the American Gastroenterological Association.
https://gastroenterology.acponline.org/archives/2023/08/25/1.htm
25 Aug 2023
NAFLD progression associated with increased mortality risk
Patients with stage F4 nonalcoholic fatty liver disease (NAFLD) have significantly increased risk for liver-related complications, type 2 diabetes, and all-cause mortality compared to those with earlier stages, an observational prospective study found.
https://gastroenterology.acponline.org/archives/2021/10/22/3.htm
22 Oct 2021
Noninvasive methods as good as biopsy for NAFLD prognosis, meta-analysis finds
An analysis of patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) compared the prognostic value of liver stiffness measured by vibration-controlled transient elastography, fibrosis-4 index, and NAFLD fibrosis score.
https://gastroenterology.acponline.org/archives/2023/06/23/1.htm
23 Jun 2023